The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...
5 / 5 (1) |
0
Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7 billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology ...
not rated yet |
0
(HealthDay)—Social and population variations in mental diagnosis are not accounted for in the newly revised fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), according to ...
5 / 5 (2) |
1
The new feature of the antidepressant drugs of the 1990s was that they had milder side-effects than their predecessors. Combined with aggressive marketing, this meant that annual sales in Sweden increased from just under ...
not rated yet |
0
German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.
not rated yet |
0
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. ...
not rated yet |
0
French drugmaker Sanofi said Friday that it had begun building a new manufacturing facility in Vietnam to serve the expanding pharmaceutical market in southeast Asia.
not rated yet |
0
The pharmaceutical industry has pulled back on marketing to physicians and consumers, yet some enduring patterns persist. According to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health, ...
not rated yet |
0
|
Drug companies spent nearly $84 million marketing pharmaceuticals in the District of Columbia in 2011, including an outlay of nearly $19 million for gifts given to physicians, hospitals and other health care providers, according ...
not rated yet |
0
(HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has ...
not rated yet |
0
(AP)—Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.
not rated yet |
0
(Medical Xpress)—Drugs that do not represent value for money or are medically unproven may be increasingly reaching one of Europe's largest pharmaceutical markets, according to research undertaken by Cambridge ...
4 / 5 (4) |
0
|
They say the real crisis stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones.
5 / 5 (1) |
0
Conflict-of-interest statements made by physicians and scientists in their medical journal articles after they had been allegedly paid by pharmaceutical manufacturers as part of off-label marketing programs are often inadequate, ...
not rated yet |
0
India's Health Ministry said Friday it had set up an expert panel to review the operations of its drug regulatory agency, accused of colluding with pharmaceutical firms to approve drugs without trials.
not rated yet |
0
